Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'".
Authors
da Silva Filipe, A; Sreenu, V; Hughes, J; Aranday-Cortes, E; Irving, WL; Foster, GR; Agarwal, K; Rosenberg, W; Macdonald, D; Richardson, PCollections
- Centre for Immunobiology [1121]